Drugs / JW0201
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06361277 | Nov 2023 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05463497 | Jan → Mar 2022 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05814406 | Jan 2023 → Mar 2024 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT05814393 | Jan 2023 → May 2024 | type 2 diabetes mellitus | JW Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JW0201 | “Reference Drug(C2205 and JW0201) or Test Drug(JW0202 and C2202)” NCT06361277 ↗3“JW0201: single administration, Tablet, Oral, BID for 5 days” NCT05463497 ↗ |
| Route | Oral | “JW0201: single administration, Tablet, Oral, BID for 5 days” NCT05463497 ↗ |